Business Wire

TEMENOS

16.3.2021 08:32:07 CET | Business Wire | Press release

Share
FINCI Goes Live with Temenos in Record Time in Less Than 4 Months

Temenos (SIX: TEMN), the banking software company, today announced that FINCI , a Lithuanian fintech company, has gone live with Temenos. FINCI is running next generation Temenos Payments on cloud-native technology along with Temenos Transact core banking on the same environment. This allows FINCI users to send, manage and receive instant multi-currency payments alongside with possibility for further extension of intelligent financial management tools all within a single app.

FINCI aims to simplify daily financial management for private individuals, entrepreneurs, freelancers, start-ups and already successfully working businesses of different industries by automating stressful and time-consuming financial and accounting tasks in a single, powerful App. Temenos’ rich banking functionality and API-first, microservices-based technology enabled FINCI to design, build and launch the service from scratch in just 4 months. With new open banking regulations, Temenos’ APIs also allow FINCI to integrate quickly with a wide range of external systems to help create its multiple intelligent financial management applications and drive its product and service innovation. FINCI will initially be available in the Baltic States and Poland with plans to extend the offering to the customers in other European countries and the UK.

Temenos’ cloud-native technology provides a flexible and agile platform that enabled FINCI to quickly build and launch new payment products that are PSD2 compatible with a high level of automation and where all appropriate fraud checks are applied seamlessly. This gives customers peace of mind and allows FINCI to focus on the customer experience and ease of use, knowing that Temenos Payments is efficiently accommodating all processing, monitoring and compliance needs.

Maksim Paukov, acting Chief Information Officer, Finci Technology, commented: “Temenos has enabled FINCI to take advantage of the opportunities arising from the emergence of an open banking market. We think of FINCI as an innovative and advanced platform for your business and personal financial life. At start, FINCI will offer daily financial products such as accounts, payments, currency exchange and payment cards. We develop our products fast and many great services and features, especially for business clients will be added shortly. With Temenos’ cloud-native technology we have a robust payments capability that is fast, secure and compatible with all the various payment regulations in the markets in which we will operate. The flexibility and agility of the Temenos platform will enable us to quickly create and launch financial products while continuing to innovate the customer experience that differentiates our service.”

David Macdonald, President of Europe, Temenos, said: “We are proud to celebrate the launch of FINCI. Temenos has become the de facto tech technology platform of choice for digital challenger banks and fintechs that want to launch fast and innovate rapidly. As FINCI has shown, our technology enables challengers to create hyper-efficient business models that deliver more value to their customers. Temenos has a strong presence in the CEE region and we look forward to supporting FINCI as it expands into new markets and leverages the agile product building capabilities of our platform to enhance its offering and bring innovative new ways to improve its customers’ financial lives.”

Award-winning Temenos Payments provides coverage for an extensive range of payment types, payment schemes, payment formats, and transaction types. When acting as a centralized hub, the solution standardizes, automates, and integrates payment flows, efficiently linking multiple payment sources and channels with multiple clearing and distribution networks and services.

FINCI also benefits from Temenos’ integrated Financial Crime Mitigation (FCM), covering watch list screening, anti-money laundering, fraud prevention and KYC with a flexible range of intelligent and versatile solutions to enhance detection and reduce cost. Temenos FCM is componentized and can be deployed in its entirety or partially to cover only specific business needs. This allows FINCI to add capability as its needs change and evolve.

FINCI joins more than 60 challenger banks and financial companies across the globe such as Alba , Banco del Sol , FlowBank , Flowe , Lunar , Next Commercial Bank , Varo Bank and WeLab Bank , making Temenos the de facto technology provider of choice for companies seeking to launch quickly and innovate at speed at the financial services market.

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an

Vonage and ServiceNow Expand their Partnership24.3.2026 09:20:00 CET | Press release

Vonage Contact Center with ServiceNow Voice integrates enterprise-grade voice and AI capabilities directly into enterprise workflows, boosting agent productivity and customer engagement Vonage, part of Ericsson (NASDAQ: ERIC), today announced the launch of its native integration with ServiceNow Voice, built on the ServiceNow AI Platform, embedding enterprise-grade voice and real-time AI capabilities directly into ServiceNow Customer Service Management (CSM) and IT Service Management (ITSM) workflows for Vonage Contact Center (VCC) customers. Vonage provides a unified service environment for enterprise customer service and IT support teams, enabling agents to deliver exceptional customer experiences while driving improvements to service performance. The integration of VCC with ServiceNow embeds real-time voice and AI capabilities into enterprise workflows, giving them the tools their agents need to streamline case progression, automate workflows, and reduce manual effort. Through the Vo

Omnes Partners With Apex Group to Tokenise Institutional Bitcoin Mining Structured Note on Base24.3.2026 09:00:00 CET | Press release

Omnes today announced a strategic partnership with Apex Group, a leading global financial services provider with over $3.5 trillion in assets serviced, to tokenise its flagship Omnes Mining Note "OMN". The OMN is an institutional grade structured note backed by Bitcoin hashrate, to be issued and managed on the Base Chain, the Ethereum L2 incubating at Coinbase, leveraging Apex Digital 3.0 for comprehensive tokenisation, administration, and transfer agency services as a fully integrated end to end solution. The OMN provides professional non-US investors with direct economic exposure to new Bitcoin production measured in hashrate, which is the computational power used to validate transactions and produce Bitcoin, without the operational complexities of managing mining infrastructure, hardware, energy, or regulatory hurdles. Issued as a secured debt note in Luxembourg, the tokenised OMN combines traditional financial structuring with blockchain enabled features, including on chain transfe

Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release

Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri

AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release

From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye